Study M832
Study name | Moorkoth S 2021 |
Title | Antidepressant-like effect of dehydrozingerone from Zingiber officinale by elevating monoamines in brain: in silico and in vivo studies |
Overall design | The aim of this study was to evaluate the involvement of MAO-A inhibitory activity of dehydrozingerone for its antidepressant activity by computational based in silico molecular docking and molecular dynamics simulation study followed by in vivo rodent model and LC-MS-based estimation of neurotransmitter level. C57BL/6 mice were divided into the following 4 groups (n = 6 per group): (1) control group, (2) escitalopram group (escitalopram for 7 days, 10 mg/kg, p.o.), (3) dehydrozingerone 1h group (dehydrozingerone for 7 days, 100 mg/kg, p.o., 1-hour after treatment), and (4) dehydrozingerone 3h group (dehydrozingerone for 7 days, 100 mg/kg, p.o., 3-hour after treatment). Dopamine, norepinephrine, and serotonin concentrations in the brain were determined by LC-MS. |
Study Type | Type3; |
Data available | Unavailable |
Organism | Mouse; C57BL/6 mouse; |
Categories of depression | Healthy individuals; Healthy individuals; Healthy individuals; |
Criteria for depression | Forced swimming test, tail suspension test |
Sample size | 24 |
Tissue | Central; Brain; Brain; |
Platform | MS-based; LC-MS: UHPLC-MS with Dionex Ultimate 3000 liquid chromatograph with LTQ XL (Thermo Scientific); |
PMID | |
DOI | |
Citation | Moorkoth S, Prathyusha NS, Manandhar S, et al. Antidepressant-like effect of dehydrozingerone from Zingiber officinale by elevating monoamines in brain: in silico and in vivo studies. Pharmacol Rep. 2021 Oct;73(5):1273-1286. |
Metabolite |
